Fluoxetine Can Inhibit SARS-CoV-2 In Vitro.
Type de document :
Article dans une revue scientifique: Article original
PMID :
URL permanente :
Titre :
Fluoxetine Can Inhibit SARS-CoV-2 In Vitro.
Auteur(s) :
Dechaumes, Arthur [Auteur]
Laboratoire de Virologie - ULR 3610 [Laboratoire de Virologie]
Nekoua, Magloire Pandoua [Auteur]
Laboratoire de virologie - ULR 3610
Belouzard, Sandrine [Auteur]
Centre d'Infection et d'Immunité de Lille (CIIL) - U1019 - UMR 9017
Sane, Famara [Auteur]
Laboratoire de virologie - ULR 3610
Engelmann, Ilka [Auteur]
Laboratoire de Virologie - ULR 3610 [Laboratoire de Virologie]
Dubuisson, Jean [Auteur]
Centre d'Infection et d'Immunité de Lille (CIIL) - U1019 - UMR 9017
Alidjinou, Enagnon Kazali [Auteur]
Laboratoire de virologie - ULR 3610
Hober, Didier [Auteur]
Laboratoire de virologie - ULR 3610
Laboratoire de Virologie - ULR 3610 [Laboratoire de Virologie]
Nekoua, Magloire Pandoua [Auteur]
Laboratoire de virologie - ULR 3610
Belouzard, Sandrine [Auteur]
![refId](/themes/Mirage2//images/idref.png)
Centre d'Infection et d'Immunité de Lille (CIIL) - U1019 - UMR 9017
Sane, Famara [Auteur]
![refId](/themes/Mirage2//images/idref.png)
Laboratoire de virologie - ULR 3610
Engelmann, Ilka [Auteur]
Laboratoire de Virologie - ULR 3610 [Laboratoire de Virologie]
Dubuisson, Jean [Auteur]
![refId](/themes/Mirage2//images/idref.png)
Centre d'Infection et d'Immunité de Lille (CIIL) - U1019 - UMR 9017
Alidjinou, Enagnon Kazali [Auteur]
![refId](/themes/Mirage2//images/idref.png)
Laboratoire de virologie - ULR 3610
Hober, Didier [Auteur]
![refId](/themes/Mirage2//images/idref.png)
Laboratoire de virologie - ULR 3610
Titre de la revue :
Microorganisms
Nom court de la revue :
Microorganisms
Numéro :
9
Pagination :
339
Date de publication :
2021-02-14
ISSN :
2076-2607
Mot(s)-clé(s) en anglais :
SARS-CoV-2
coronavirus
fluoxetine
in vitro
coronavirus
fluoxetine
in vitro
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
An outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) resulted in the coronavirus disease pandemic, drastically affecting global health and economy. Though the understanding of the disease has improved, ...
Lire la suite >An outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) resulted in the coronavirus disease pandemic, drastically affecting global health and economy. Though the understanding of the disease has improved, fighting the virus remains challenging. One of the strategies is repurposing existing drugs as inhibitors of SARS-CoV-2. Fluoxetine (FLX), a selective serotonin reuptake inhibitor, reportedly inhibits the replication of RNA viruses, especially Coxsackieviruses B (CVB), such as CV-B4 in vitro and in vivo. Therefore, in this study, we investigated the in vitro antiviral activity of FLX against SARS-CoV-2 in a model of acute infection. When 10 μM of FLX was added to SARS-CoV-2-infected Vero E6 cells, the virus-induced cytopathic effect was not observed. In this model, the level of infectious particles in the supernatant was lower than that in controls. The level was below the limit of detection of the assay up to day 3 post-infection when FLX was administered before viral inoculation or simultaneously followed by daily inoculation. In conclusion, FLX can inhibit SARS-CoV-2 in vitro. Further studies are needed to investigate the potential value of FLX to combat SARS-CoV-2 infections, treat SARS-CoV-2-induced diseases, and explain the antiviral mechanism of this molecule to pave way for novel treatment strategies.Lire moins >
Lire la suite >An outbreak of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) resulted in the coronavirus disease pandemic, drastically affecting global health and economy. Though the understanding of the disease has improved, fighting the virus remains challenging. One of the strategies is repurposing existing drugs as inhibitors of SARS-CoV-2. Fluoxetine (FLX), a selective serotonin reuptake inhibitor, reportedly inhibits the replication of RNA viruses, especially Coxsackieviruses B (CVB), such as CV-B4 in vitro and in vivo. Therefore, in this study, we investigated the in vitro antiviral activity of FLX against SARS-CoV-2 in a model of acute infection. When 10 μM of FLX was added to SARS-CoV-2-infected Vero E6 cells, the virus-induced cytopathic effect was not observed. In this model, the level of infectious particles in the supernatant was lower than that in controls. The level was below the limit of detection of the assay up to day 3 post-infection when FLX was administered before viral inoculation or simultaneously followed by daily inoculation. In conclusion, FLX can inhibit SARS-CoV-2 in vitro. Further studies are needed to investigate the potential value of FLX to combat SARS-CoV-2 infections, treat SARS-CoV-2-induced diseases, and explain the antiviral mechanism of this molecule to pave way for novel treatment strategies.Lire moins >
Audience :
Internationale
Vulgarisation :
Non
Établissement(s) :
Université de Lille
CHU Lille
CHU Lille
Collections :
Date de dépôt :
2024-01-17T22:17:50Z
2024-02-07T14:43:12Z
2024-02-07T14:43:12Z
Fichiers
- microorganisms-09-00339.pdf
- Non spécifié
- Accès libre
- Accéder au document